The spectrum of vaccine therapies for patients with glioblastoma multiforme

Related Experiment Video

Updated: May 19, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Laura K Aguilar1, Mariel Arvizu, Estuardo Aguilar-Cordova

  • 1Advantagene Inc, 440 Lexington St, Auburndale, MA 02466, USA. lkaguilar@advantagene.com

Current Treatment Options in Oncology
|August 21, 2012
PubMed
Abstract

Insights

Glioblastoma multiforme (GBM) remains a lethal brain cancer despite aggressive treatments. Emerging immunotherapies show promise for improved efficacy and safety in treating this complex disease.

Area of Science:

  • Neuro-oncology
  • Cancer immunotherapy
  • Central nervous system (CNS) tumors

Background:

  • Glioblastoma multiforme (GBM) is the most prevalent and lethal primary malignant brain tumor.
  • Current treatments (surgery, radiation, chemotherapy) offer limited survival benefits (median < 15 months).
  • Therapeutic development is hindered by GBM's complexity and CNS-specific protective mechanisms.

Purpose of the Study:

  • To review recent advancements in understanding GBM pathogenesis.
  • To discuss novel, targeted therapeutic strategies for malignant gliomas.
  • To highlight the potential of immunotherapy in GBM treatment.

Main Methods:

  • Review of current literature on glioblastoma multiforme.
  • Analysis of emerging immunotherapy approaches for brain tumors.
  • Discussion of clinical trial data and therapeutic efficacy.

Main Results:

  • Understanding GBM pathogenesis is paving the way for targeted therapies.
  • Immunotherapy approaches demonstrate significant therapeutic efficacy.
  • Immunotherapies exhibit a favorable safety profile for GBM treatment.

Conclusions:

  • Novel targeted therapies are emerging due to a better understanding of GBM.
  • Immunotherapy represents a promising avenue for treating glioblastoma multiforme.
  • Further research into immunotherapy is crucial for improving patient outcomes in GBM.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...